Risk of first venous thrombosis risk for strata of free protein S levels
| Range . | Observation years (relatives) . | Relatives with event . | Annual incidence, % (95% CI) . | Crude HR (95% CI) . | Adjusted HR* (95% CI) . | Adjusted HR† (95% CI) . | Adjusted HR (95% CI) adjusted for . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Antithrombin deficiency . | Protein C deficiency . | Factor V Leiden . | Prothrombin G20210A . | High factor VIII . | |||||||
| > 75th percentile(> 91 IU/dL) | 8586(n = 291) | 17 | 0.20(0.11–0.32) | Reference | Reference | Reference | Reference | Reference | Reference | Reference | Reference |
| 50th–75th percentile(79–90 IU/dL) | 8044(n = 285) | 17 | 0.21(0.12–0.34) | 1.0(0.5–2.1) | 0.9(0.4–2.0) | 1.0(0.4–2.3) | 1.2(0.6–2.4) | 1.0(0.5–2.0) | 1.1(0.6–2.2) | 1.1(0.6–2.2) | 1.0(0.5–2.1) |
| 25th–50th percentile(65–78 IU/dL) | 9168(n = 308) | 28 | 0.31(0.20–0.44) | 1.5(0.8–2.8) | 1.4(0.7–2.8) | 1.2(0.5–2.8) | 1.7(0.9–3.2) | 1.5(0.8–2.8) | 1.6(0.8–2.9) | 1.6(0.9–3.0) | 1.4(0.8–2.6) |
| 5th–25th percentile(41–64 IU/dL) | 5856(n = 205) | 15 | 0.26(0.14–0.42) | 1.2(0.6–2.4) | 1.1(0.5–2.6) | 1.1(0.5–2.5) | 1.6(0.8–3.3) | 1.3(0.6–2.6) | 1.3(0.6–2.6) | 1.3(0.6–2.6) | 1.2(0.6–2.4) |
| < 5th percentile(< 41 IU/dL) | 1589(n = 54) | 19 | 1.20(0.72–1.87) | 5.7(2.9–10.9) | 5.6(2.7–11.5) | 5.9(2.9–12.0) | 5.9(3.0–11.5) | 3.9(1.9–7.8) | 5.7(2.9–11.1) | 5.9(3.0–11.6) | 5.7(3.0–11.1) |
| < 2.5th percentile(< 33 IU/dL) | 828(n = 28) | 15 | 1.81(1.01–2.99) | 10.8(5.2–22.1) | 11.3(5.4–23.6) | 11.8(5.5–25.6) | 9.3(4.5–19.2) | 7.6(3.5–16.2) | 11.1(5.2–23.5) | 11.3(5.4–23.5) | 10.9(5.3–22.5) |
| Range . | Observation years (relatives) . | Relatives with event . | Annual incidence, % (95% CI) . | Crude HR (95% CI) . | Adjusted HR* (95% CI) . | Adjusted HR† (95% CI) . | Adjusted HR (95% CI) adjusted for . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Antithrombin deficiency . | Protein C deficiency . | Factor V Leiden . | Prothrombin G20210A . | High factor VIII . | |||||||
| > 75th percentile(> 91 IU/dL) | 8586(n = 291) | 17 | 0.20(0.11–0.32) | Reference | Reference | Reference | Reference | Reference | Reference | Reference | Reference |
| 50th–75th percentile(79–90 IU/dL) | 8044(n = 285) | 17 | 0.21(0.12–0.34) | 1.0(0.5–2.1) | 0.9(0.4–2.0) | 1.0(0.4–2.3) | 1.2(0.6–2.4) | 1.0(0.5–2.0) | 1.1(0.6–2.2) | 1.1(0.6–2.2) | 1.0(0.5–2.1) |
| 25th–50th percentile(65–78 IU/dL) | 9168(n = 308) | 28 | 0.31(0.20–0.44) | 1.5(0.8–2.8) | 1.4(0.7–2.8) | 1.2(0.5–2.8) | 1.7(0.9–3.2) | 1.5(0.8–2.8) | 1.6(0.8–2.9) | 1.6(0.9–3.0) | 1.4(0.8–2.6) |
| 5th–25th percentile(41–64 IU/dL) | 5856(n = 205) | 15 | 0.26(0.14–0.42) | 1.2(0.6–2.4) | 1.1(0.5–2.6) | 1.1(0.5–2.5) | 1.6(0.8–3.3) | 1.3(0.6–2.6) | 1.3(0.6–2.6) | 1.3(0.6–2.6) | 1.2(0.6–2.4) |
| < 5th percentile(< 41 IU/dL) | 1589(n = 54) | 19 | 1.20(0.72–1.87) | 5.7(2.9–10.9) | 5.6(2.7–11.5) | 5.9(2.9–12.0) | 5.9(3.0–11.5) | 3.9(1.9–7.8) | 5.7(2.9–11.1) | 5.9(3.0–11.6) | 5.7(3.0–11.1) |
| < 2.5th percentile(< 33 IU/dL) | 828(n = 28) | 15 | 1.81(1.01–2.99) | 10.8(5.2–22.1) | 11.3(5.4–23.6) | 11.8(5.5–25.6) | 9.3(4.5–19.2) | 7.6(3.5–16.2) | 11.1(5.2–23.5) | 11.3(5.4–23.5) | 10.9(5.3–22.5) |
Number of relatives with protein S type III deficiency (free protein S levels < 65 IU/dL) was 259 (23%).
HR denotes hazard ratio.
Adjusted for age, sex, and clustering of events within families.
Excluding women who used estrogens at time of venous thrombosis or at enrollment (n = 127) and adjusted for age, sex, and clustering of events within families.